Inicio > PEÑARRUBIA PONCE, MARIA JESUS

PEÑARRUBIA PONCE, MARIA JESUS

PROFESOR ASOCIADO CIENCIAS DE LA SALUD
Medicina, Dermatología y Toxicología
 
mariajesus.penarrubia@uva.es

Índice H en Scopus: 21
 

[][com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=84112]], camposKey:1876-0341 2024-06-01 COVID-19-associated pulmonary aspergillosis (CAPA) in hematological patients: Could antifungal prophylaxis be necessary? A nationwide study939946, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=75590]], camposKey:0006-4971 2023-01-26 Novel variants in GALE cause syndromic macrothrombocytopenia by disrupting glycosylation and thrombopoiesis406421, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=75591]], camposKey:2077-0383 2022-06-01 Full Characterization of Thrombotic Events in All Hospitalized COVID-19 Patients in a Spanish Tertiary Hospital during the First 18 Months of the Pandemic00, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=75592]], camposKey:2296-858X 2022-04-25 ABO Blood System and COVID-19 Susceptibility: Anti-A and Anti-B Antibodies Are the Key Points00, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=75593]], camposKey:0732-183X 2022-01-20 Romidepsin Plus CHOP Versus CHOP in Patients With Previously Untreated Peripheral T-Cell Lymphoma: Results of the Ro-CHOP Phase III Study (Conducted by LYSA)242251, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=75594]], camposKey:2284-2594 2022-01-01 Fibrinogen Deficiency with Thrombotic Manifestations00, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=65938]], camposKey:1664-3224 2021-10-13 Can the Cytokine Profile According to ABO Blood Groups Be Related to Worse Outcome in COVID-19 Patients? Yes, They Can00, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=74163]], camposKey:2075-4426 2021-07-01 Evaluation of cytokines as robust diagnostic biomarkers for COVID-19 detection00, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=83203]], camposKey:2077-0383 2021-05-01 HGF, IL-1¿, and IL-27 are robust biomarkers in early severity stratification of COVID-19 patients00, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=66945]], camposKey:0006-4971 2021-04-08 Chemotherapy or allogeneic transplantation in high-risk Philadelphia chromosome¿negative adult lymphoblastic leukemia18791894, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=84113]], camposKey:2045-7634 2021-02-01 R-COMP versus R-CHOP as first-line therapy for diffuse large B-cell lymphoma in patients ¿60 years: Results of a randomized phase 2 study from the Spanish GELTAMO group13141326, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=76541]], camposKey:2077-0383 2021-01-01 Predictive modeling of poor outcome in severe covid-19: A single-center observational study based on clinical, cytokine and laboratory profiles00, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=66946]], camposKey:0939-5555 2020-04-01 RELINF: prospective epidemiological registry of lymphoid neoplasms in Spain. A project from the GELTAMO group799808, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=61691]], camposKey:1664-2295 2020-01-01 Neurological Comorbidity Is a Predictor of Death in Covid-19 Disease: A Cohort Study on 576 Patients00, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=84114]], camposKey:2572-9241 2020-01-01 Results of an early access treatment protocol of daratumumab monotherapy in spanish patients with relapsed or refractory multiple myeloma00, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=52143]], camposKey:0902-4441 2020-01-01 Use of eltrombopag for patients 65 years old or older with immune thrombocytopenia259270, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=84115]], camposKey:1042-8194 2018-07-03 Efficacy and safety of native versus pegylated Escherichia coli asparaginase for treatment of adults with high-risk, Philadelphia chromosome-negative acute lymphoblastic leukemia16341643, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=84116]], camposKey:0361-8609 2018-07-01 A new prognostic model identifies patients aged 80 years and older with diffuse large B-cell lymphoma who may benefit from curative treatment: A multicenter, retrospective analysis by the Spanish GELTAMO group867873, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=47734]], camposKey:0019-9567 2018-01-01 Polymorphisms in receptors involved in opsonic and nonopsonic phagocytosis, and correlation with risk of infection in oncohematology patients00, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=84117]], camposKey:1042-8194 2017-05-04 The number of tumor infiltrating T-cell subsets in lymph nodes from patients with Hodgkin lymphoma is associated with the outcome after first line ABVD therapy*11441152, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=47736]], camposKey:0925-5710 2017-01-01 Efficacy and safety of eltrombopag in persistent and newly diagnosed ITP in clinical practice508516, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=47739]], camposKey:0902-4441 2016-09-01 Eltrombopag safety and efficacy for primary chronic immune thrombocytopenia in clinical practice297302, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=84118]], camposKey:2045-7634 2015-07-01 Switching to second-generation tyrosine kinase inhibitor improves the response and outcome of frontline imatinib-treated patients with chronic myeloid leukemia with more than 10% of BCR-ABL/ABL ratio at 3 months9951002, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=47745]], camposKey:0361-8609 2015-01-01 Successful discontinuation of eltrombopag after complete remission in patients with primary immune thrombocytopenia00, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=84119]], camposKey:0361-8609 2014-11-01 Do chronic myeloid leukemia patients with late ¿warning¿ responses benefit from ¿watch and wait¿ or switching therapy to a second generation tyrosine kinase inhibitor?00, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=68838]], camposKey:0902-4441 2014-11-01 Genomic analysis of clonal eosinophils by CGH arrays reveals new genetic regions involved in chronic eosinophilia422428, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=22426]], camposKey:0210-5705 2014-01-01 Linfoma MALT y tumor carcinoide sincrónicos de íleon9596, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=56309]], camposKey:0210-5705 2014-01-01 Synchronic MALT lymphoma and carcinoid tumor of the ileum Linfoma MALT y tumor carcinoide sincrónicos de íleon9596, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=22427]], camposKey:0210-6523 2013-01-01 Linfoma de Hodgkin259271, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=84120]], camposKey:0902-4441 2012-07-01 Incidence and clinical characteristics of myeloproliferative neoplasms displaying a PDGFRB rearrangement3741, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=84121]], camposKey:0732-183X 2010-08-20 Therapy-related myeloid neoplasms in patients with acute promyelocytic leukemia treated with all-trans-retinoic acid and anthracycline-based chemotherapy38723879, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=68846]], camposKey:0390-6078 2010-05-01 Long FLT3 internal tandem duplications and reduced PML-RAR¿ expression at diagnosis characterize a high-risk subgroup of acute promyelocytic leukemia patients745751, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=68849]], camposKey:0145-2126 2009-12-01 High FOXO3a expression is associated with a poorer prognosis in AML with normal cytogenetics17061709, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=84122]], camposKey:1042-8194 2009-12-01 Influence of MBL-2 mutations in the infection risk of patients with follicular lymphoma treated with rituximab, fludarabine, and cyclophosphamide12831289, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=47750]], camposKey:0145-2126 2009-06-01 Hematologic and cytogenetic response to lenalidomide in de novo acute myeloid leukemia with chromosome 5q deletion00, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=84123]], camposKey:0008-543X 2009-05-01 Efficacy and safety of Liposomal cytarabine in lymphoma Patients with central nervous system involvement from lymphoma18921898, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=68852]], camposKey:0006-4971 2009-01-01 Molecular stratification model for prognosis in cytogenetically normal acute myeloid leukemia148152, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=84124]], camposKey:0390-6078 2008-12-01 The relevance of preferentially expressed antigen of melanoma (PRAME) as a marker of disease activity and prognosis in acute promyelocytic leukemia17971805, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=68150]], camposKey:1130-0108 2008-08-01 Jejunal mucormycosis in a patient with Hodgkin's lymphoma Mucormicosis yeyunal en paciente con linfoma de Hodgkin507510, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=22429]], camposKey:0210-6523 2008-01-01 Nuevas perspectivas en el tratamiento y curación de las leucemias275288, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=84125]], camposKey:1083-8791 2007-12-01 Veno-Occlusive Disease of the Liver after High-Dose Cytoreductive Therapy with Busulfan and Melphalan for Autologous Blood Stem Cell Transplantation in Multiple Myeloma Patients14481454, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=84126]], camposKey:1699-048X 2006-12-01 Diagnosis of a primary testicular lymphoma by echography and magnetic resonance imaging456458, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=47753]], camposKey:0929-5305 2006-01-01 Oral anticoagulant treatment: Risk factors involved in 500 intracranial hemorrhages113120, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=47755]], camposKey:1130-0108 2005-09-01 Primary biliary cirrhosis, "sicca" syndrome and autoimmune hemolytic anemia [5] Cirrosis biliar primaria, síndrome "sicca" y anemia hemolítica autoinmune678679, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=22428]], camposKey:0210-6523 2005-01-01 Tratamiento del mieloma múltiple con trasplante autólogo de progenitores hematopoyéticos93109, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=38347]], camposKey:0009-7330 2004-01-01 Experimental and clinical regenerative capability of human bone marrow cells after myocardial infarction742748, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=47713]], camposKey:0300-8932 2004-01-01 Intracoronary stem cell transplantation in acute myocardial infarction Regeneración miocárdica mediante la implantación intracoronaria de células madre en el infarto agudo de miocardio201208, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=14434]], camposKey:0300-8932 2004-01-01 Regeneración miocárdica mediante la implantación intracoronaria de células madre en el infarto agudo de miocardio201208, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=84127]], camposKey:0939-5555 2003-12-01 A randomized study of intermediate as compared with high doses of interferon-alpha for chronic myeloid leukemia: No differences in cytogenetic responses750758, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=84128]], camposKey:0006-4971 2003-10-15 Marrow versus peripheral blood for geno-identical allogeneic stem cell transplantation in acute myelocytic leukemia: Influence of dose and stem cell source shows better outcome with rich marrow30433051, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=47758]], camposKey:1466-4860 2003-08-11 Emphysematous gastritis and severe aplastic anemia8284, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=84129]], camposKey:0390-6078 2003-04-01 Lack of influence of human immunodeficiency virus infection status in the response to therapy and survival of adult patients with mature B-cell lymphoma or leukemia. Results of the PETHEMA-LAL3/97 study445453, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=84130]], camposKey:1466-4860 2000-01-01 Are myeloma patients with renal failure candidates for autologous stem cell transplantation?2836, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=84131]], camposKey:0036-4355 1998-10-01 Lymphoblastoid alpha interferon treatment in patients with chronic myeloid leukaemia refractory to recombinant alpha interferon Tratamiento con interferon alfa linfoblastoide en pacientes con leucemia mieloide crónica resistente a interferon alfa 2 recombinante443447, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=84132]], camposKey:0036-4355 1997-04-01 Tratamiento de mantenimiento con interferón alfa en mieloma múltiple tras autotrasplante de progenitores hematopoyéticos de sangre periférica3441, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=84133]], camposKey:0364-2348 1997-01-01 Magnetic resonance imaging features of chloroma of the shoulder7072, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=84134]], camposKey:0361-8609 1996-11-01 Southern technique and cytogenetics are complementary and must be used together in the evaluation of Ph1, M-BCR positive chronic myeloid leukemia (CML) patients treated with alpha interferon (IFN-alpha)169174, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=84135]], camposKey:0014-2565 1996-08-01 Imipenem combined with ieicoplanin or vancomycin in the initial empiric therapy of febrile neutropenia. Analysis of the primary response and of an overall sequential strategy in 126 episodes Imipenem combinado con teicoplanina o vancomicina en el tratamiento empírico inicial de la neutropenia febril. Análisis de la respuesta primaria y de una estrategia secuencial global en 126 episodios515522, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=84138]], camposKey:0025-7753 1995-01-01 Allogeneic bone marrow transplantation in chronic myeloid leukemia. Clinical results and risk factors in 70 patients TRASPLANTE ALOGENICO DE MEDULO OSEA EN LA LEUCEMIA MIELOIDE CRONICA. RESULTADOS CLINICOS Y FACTORES DE RIESGO EN 70 PACIENTES605611, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=84136]], camposKey:0361-8609 1995-01-01 Hypertriglyceridemia may be severe in CML patients treated with interferon¿¿240241, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=84137]], camposKey:0018-5043 1995-01-01 Subacute thyroiditis associated with interferon-¿2a therapy [1]4546, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=84139]], camposKey:0036-4355 1994-01-01 Early bacterial infections in 103 patients with bone-marrow transplants INFECCIONES BACTERIANAS PRECOCES EN 103 PACIENTES TRATADOS CON TRASPLANTE DE MEDULA OSEA191196][][][][][][][][][][][com.sigma.fs3.argos.domain.gpc.GpcTesis[id=com.sigma.fs3.argos.domain.gpc.GpcTesisPK[ifcactivitat=TES, ifccomptador=30936]]][][][][][][][][][][com.sigma.fs3.argos.domain.gpc.ayudasrecerca.ConvenisPPC@611798, com.sigma.fs3.argos.domain.gpc.ayudasrecerca.ConvenisPPC@611797, com.sigma.fs3.argos.domain.gpc.ayudasrecerca.ConvenisPPC@611796, com.sigma.fs3.argos.domain.gpc.ayudasrecerca.ConvenisPPC@61177b, com.sigma.fs3.argos.domain.gpc.ayudasrecerca.ConvenisPPC@611799, com.sigma.fs3.argos.domain.gpc.ayudasrecerca.ConvenisPPC@611789, com.sigma.fs3.argos.domain.gpc.ayudasrecerca.ConvenisPPC@612490, com.sigma.fs3.argos.domain.gpc.ayudasrecerca.ConvenisPPC@611364][][][][][][][][][][][][][][][]

AYUDA A LA INVESTIGACIÓN

PUBLICACIONES

Artículos de revista (62)

Tamayo-Velasco A.; Lopez-Herrero R.; Gomez-Garcia L.M.; Sanchez-de Prada L.; Aguilar-Monserrate G.; Martin-Fernandez M.; Bardaji-Carrillo M.; Alvaro-Meca A.; Tamayo E.; Resino S.; Miramontes-Gonzalez J.P.; Peñarrubia-Ponce M.J. COVID-19-associated pulmonary aspergillosis (CAPA) in hematological patients: Could antifungal prophylaxis be necessary? A nationwide study . Journal of Infection and Public Health 2024; 17(6): 939-946.

Enlace a la publicación
Ver Todos
 

AYUDA A LA INVESTIGACIÓN

Convenios/Contratos OTC (8)

ESTUDIO FASE III, PROSPECTIVO, ALEATORIZADO, ABIERTO, CON DOS BRAZOS DE TRATAMIENTO, PARA EVALUAR LA TASA DE REMISIÓN LIBRE DE TRATAMIENTO (RLT) EN PACIENTES CON LMC CROMOSOMA FILADELFIA POSITIVO, DESPUÉS DE DOS DURACIONES DISTINTAS DE TRATAMIENTO DE CONSOLIDACIÓN CON NILOTINIB 300 MG BID. . Equipo Investigadores: PEÑARRUBIA PONCE, MARIA JESUS (IP). Entidades Participantes: FUNDACION GENERAL DE LA UNIVERSIDAD DE VALLADOLID.. Entidades Financiadoras: NOVARTIS FARMACEUTICA SA .. 13/06/2013

Ver Todos
 

OTROS

Tesis doctorales (1)


Texto completo en acceso abierto  
Ver Todos
Cargando información ...
Universidad de Valladolid - Copyright Universidad de Valladolid - Todos los derechos reservados